

# Thomas M Gates

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7235329/publications.pdf>

Version: 2024-02-01

20  
papers

515  
citations

840585

11  
h-index

752573

20  
g-index

22  
all docs

22  
docs citations

22  
times ranked

854  
citing authors

#	ARTICLE	IF	CITATIONS
1	Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitive disorder. <i>Aids</i> , 2016, 30, 591-600.	1.0	91
2	HIV-associated neurocognitive disorder in Australia: a case of a high-functioning and optimally treated cohort and implications for international neuroHIV research. <i>Journal of NeuroVirology</i> , 2014, 20, 258-268.	1.0	66
3	Cognitive change trajectories in virally suppressed HIV-infected individuals indicate high prevalence of disease activity. <i>PLoS ONE</i> , 2017, 12, e0171887.	1.1	52
4	The Chronicity of HIV Infection Should Drive the Research Strategy of NeuroHIV Treatment Studies: A Critical Review. <i>CNS Drugs</i> , 2016, 30, 53-69.	2.7	42
5	Functional Connectivity in Virally Suppressed Patients with HIV-Associated Neurocognitive Disorder: A Resting-State Analysis. <i>American Journal of Neuroradiology</i> , 2017, 38, 1623-1629.	1.2	38
6	Catecholamines and Paroxysmal Sympathetic Hyperactivity after Traumatic Brain Injury. <i>Journal of Neurotrauma</i> , 2017, 34, 109-114.	1.7	37
7	Imaging correlates of the blood-brain barrier disruption in HIV-associated neurocognitive disorder and therapeutic implications. <i>Aids</i> , 2019, 33, 1843-1852.	1.0	36
8	Atrophic brain signatures of mild forms of neurocognitive impairment in virally suppressed HIV infection. <i>Aids</i> , 2019, 33, 55-66.	1.0	33
9	Socioeconomic factors explain suboptimal adherence to antiretroviral therapy among HIV-infected Australian adults with viral suppression. <i>PLoS ONE</i> , 2017, 12, e0174613.	1.1	33
10	Covertly active and progressing neurochemical abnormalities in suppressed HIV infection. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e430.	3.1	22
11	HIV brain latency as measured by CSF Bcl11b relates to disrupted brain cellular energy in virally suppressed HIV infection. <i>Aids</i> , 2019, 33, 433-441.	1.0	13
12	Age-related trends in late mortality following traumatic brain injury: A multicentre inception cohort study. <i>Australasian Journal on Ageing</i> , 2015, 34, E1-E6.	0.4	11
13	How all-type dementia risk factors and modifiable risk interventions may be relevant to the first-generation aging with HIV infection?. <i>European Geriatric Medicine</i> , 2019, 10, 227-238.	1.2	11
14	An examination of reliable change methods for measuring cognitive change with the Cogstate Computerized Battery: Research and clinical implications. <i>Archives of Clinical Neuropsychology</i> , 2021, 36, 597-612.	0.3	8
15	Cognitive ageing is premature among a community sample of optimally treated people living with HIV. <i>HIV Medicine</i> , 2021, 22, 151-164.	1.0	7
16	Lack of cognitive impairment in long-term survivors of colorectal cancer. <i>Supportive Care in Cancer</i> , 2022, 30, 6123-6133.	1.0	4
17	Abnormal cognitive aging in people with HIV: evidence from data integration between two countries' cohort studies. <i>Aids</i> , 2022, 36, 1171-1179.	1.0	4
18	External causes of death after severe traumatic brain injury in a multicentre inception cohort: clinical description and risk factors. <i>Brain Injury</i> , 2019, 33, 821-829.	0.6	3

#	ARTICLE	IF	CITATIONS
19	The impact of compensation on late mortality after traumatic brain injury: A multi-centre study. <i>Brain Injury</i> , 2017, 31, 1044-1049.	0.6	2
20	What are the predictors of TOMM failure in clinical TBI populations? A retrospective analysis. <i>Journal of the International Neuropsychological Society</i> , 0, , 1-10.	1.2	0